NCT06314698View on ClinicalTrials.gov

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

April 30, 2027

Conditions
Multiple MyelomaBone Diseases
Interventions
DRUG

Narlumosbart

Administered by subcutaneous injection once every 4 weeks.

DRUG

Denosumab

Administered by subcutaneous injection once every 4 weeks.

All Listed Sponsors
collaborator

Shanghai JMT-Bio Inc.

INDUSTRY

lead

RenJi Hospital

OTHER